Business Wire

Armis Launches Armis Centrix™, the AI-powered Cyber Exposure Management Platform

Share

Armis, the asset intelligence cybersecurity company, today announced the launch of Armis Centrix™, the AI-powered cyber exposure management platform. Armis Centrix™ is a seamless, frictionless, cloud-based platform that proactively secures all your assets, remediates vulnerabilities, blocks threats and protects your entire attack surface.

Armis Centrix™ enables organizations to discover, contextualize, enrich and profile every asset in their environment whilst also building a line of defense by leveraging Armis Centrix™ Asset Intelligence risk scores, policies, alerting and visualizations and most importantly: prioritize efforts against the exposures that matter to your business. Armis Centrix™ also integrates with existing enforcement and ticketing tools to establish end-to-end workflows and true risk lifecycle management and track risk reduction efforts to easily report on progress made. Armis Centrix™ takes proactive measures, detects threats & stops attacks to establish operational workflows and track risk reduction.

“In a perimeter-less world, where assets are digitally connected, traditional cybersecurity boundaries no longer exist. Legacy on-premise systems and point solutions are no longer fit for purpose leaving your attack surface and most critical assets open and exposed to cyber criminals and multiple bad actors,” said Nadir Izrael, CTO and Co-Founder, Armis. “The sheer scale and dynamic nature of the attack surface necessitates an entirely different, AI-driven approach, and that’s what Armis Centrix™ is - the AI that powers a suite of powerful tools for managing cyber risk exposure.”

Armis Centrix™ helps organizations see, protect and manage their entire attack surface, continuously safeguarding their mission-critical assets from cyber threats. Born in the cloud and fueled by AI, only Armis Centrix™ delivers a true modular approach to cyber exposure management covering the most critical cybersecurity needs for our clients across 4 solutions:

  • Asset management and security - Complete asset inventory of all asset types allowing any organization to see and secure the attack surface
  • OT/IOT security - See and secure OT/IOT networks and physical assets, ensure uptime and build an effective & comprehensive security strategy
  • Medical device security - Complete visibility and security for all medical devices, clinical assets and the entire healthcare ecosystem - with zero disruption to patient care
  • Vulnerability prioritization and remediation - Consolidate, prioritize and remediate all vulnerabilities; improve mean time to remediation (MTTR) with automatic remediation and ticketing workflows

“This is a revolutionary advancement that will change the way in which companies answer key questions regarding their cybersecurity posture,” said Dana Gilboa, Chief Product Officer, Armis. “Armis can help organizations mitigate their cyber asset risks and protect the entire attack surface by providing the needed intelligence to align security and business efforts. With this approach, we can ultimately provide organizations with the peace of mind they need, allowing them to see, protect and manage all their critical assets.”

Armis Centrix™ is industry-agnostic, allowing Manufacturing, Health and Medical, Information Technology, Energy and Utilities, Financial Services, Transportation, Telecommunications and Media, Public Sector and many more to benefit from its capabilities. Additionally, Armis collaborates with the world’s premier global technology vendors to ensure its customers can seamlessly integrate the Armis Centrix™ platform with existing IT and security stacks.

If you would like to know more about Armis Centrix™, the cyber exposure management platform, visit armis.com/centrix or contact us at info@armis.com.

About Armis

Armis, the asset intelligence cybersecurity company, protects the entire attack surface and manages the organization's cyber risk exposure in real time. In a rapidly evolving, perimeter-less world Armis ensures that organizations continuously see, secure, protect and manage all critical assets. Armis secures Fortune 100, 200 and 500 companies as well as national governments, state and local entities to help keep critical infrastructure, economies and society safe and secure 24/7. Armis is a privately held company headquartered in California.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Rebecca Cradick
Senior Director, Global Communications
Armis
pr@armis.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release

Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r

Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye